RESUMEN

The aim of this study was to assess the preliminary effectiveness and acceptability of an inter-professional e-consultation on vaccines. We used a quasi-experimental design to introduce an application in electronic health records that allowed primary health providers to launch e-consults to the hospital vaccines unit. A total of 135 e-consults were received during 10 months. E-consults were more frequently about subjects with chronic diseases (82.2%). Most of the e-consults were global (60.7%), that is, to revise a patient's complete vaccination schedule, whereas 39.3% were specific, that is, to request information regarding a concrete vaccine or serology, with hepatitis vaccines leading the ranking (42.9%). The e-consultation avoided hospital referral in 85.4% of the global e-consults and in 100% of the specific e-consults. Indicators of acceptability were all above nine points (10 points indicated the maximum). The best-rated aspect was the level of recommendation (9.7 ± 0.68 points). In summary, linking primary health-care providers with specialists in vaccines through an e-consultation tool is effective and well-accepted by users.

Asunto(s)

RESUMEN

Los pacientes con enfermedad inflamatoria intestinal son susceptibles de recibir tratamiento inmunomodulador y, por tanto, han de estar correctamente vacunados. Pese a la probada seguridad de las vacunas, estas no están exentas de reacciones adversas. A continuación, se presenta un caso clínico de una mujer joven con colitis ulcerosa en tratamiento con mesalazina que presentó vasculitis leucocitoclástica tras vacunación frente a neumococo, varicela y hepatitis A. Dicha reacción apenas está descrita en la literatura tras la administración de cualquiera de estas vacunas y nunca ha sido descrita en un paciente con patología de base

Patients with inflammatory bowel disease are likely to receive immunomodulation treatment and therefore, should be properly vaccinated. Despite their proven safety, vaccines are not exempt from adverse reactions. The clinical case was a young female with ulcerative colitis under mesalazine treatment, who developed leukocytoclastic vasculitis following vaccination for pneumococci, varicella and hepatitis A. This adverse reaction after the previously mentioned vaccines is barely described in the literature and has never been reported in a patient with an underlying condition

Asunto(s)

RESUMEN

Patients with inflammatory bowel disease are likely to receive immunomodulation treatment and therefore, should be properly vaccinated. Despite their proven safety, vaccines are not exempt from adverse reactions. The clinical case was a young female with ulcerative colitis under mesalazine treatment, who developed leukocytoclastic vasculitis following vaccination for pneumococci, varicella and hepatitis A. This adverse reaction after the previously mentioned vaccines is barely described in the literature and has never been reported in a patient with an underlying condition.

Asunto(s)

RESUMEN

Introducción. La coinfección por virus de hepatitis B (VHB) en pacientes con virus de inmunodeficiencia humana (VIH) aumenta la morbimortalidad asociada. La vacunación frente al VHB ha mostrado ser el método más efectivo para prevenir esta situación. Los esquemas de vacunación estándar utilizados en esta población no parecen ser suficientemente efectivos. El objetivo es conocer la tasa de respondedores tras el uso de la vacuna de hepatitis B adyuvada con AS04C en pacientes VIH, así como las posibles reacciones adversas asociadas. Métodos. Estudio analítico observacional con una cohorte retrospectiva de pacientes VIH positivos vacunados y dados de alta en 2016 de la Unidad de Vacunas de un Servicio de Medicina Preventiva y Salud Pública. Se incluyeron los pacientes que presentaban antiHBs (-), antiHBcActot (-) y HBsAg (-) a nivel basal, sin haber recibido previamente vacunación frente al VHB. Se utilizó la vacuna frente al VHB adyuvada con AS04C en pauta de 4 dosis (0-1-2-6 meses). Cuando antiHBs <10 UI/mL tras la primovacunación, se aplicaron 2 dosis más de la misma vacuna separadas de 30 días. Resultados. Se incluyeron un total de 39 pacientes. De ellos, 74,4% fueron hombres. La media de edad fue 47,26 años. Se observó una tasa de respondedores tras la primovacunación superior al 92% y hasta el 100% con las dos dosis posteriores. No se detectó ninguna reacción adversa tras la vacunación. Conclusión: la administración en pacientes VIH de vacuna frente a hepatitis B adyuvada con AS04C registró una tasa de respuesta del 100% mostrando, además, un excelente perfil de seguridad

Introduction. Co-infection with hepatitis B virus (HBV) in patients with human immunodeficiency virus (HIV) increases associated morbidity and mortality. Vaccination against HBV has been shown to be the most effective method to prevent this situation. Standard vaccination schemes used in this population do not appear to be effective enough. The objective is to identify the response rate following the use of AS04C-adjuvanted hepatitis B vaccine in HIV patients as well as the possible associated adverse reactions. Methods. An observational, analytical study with a retrospective cohort of HIV positive patients discharged in 2016 from the Vaccines Unit of a Preventive Medicine and Public Health Service. Patients with antiHBs (-), antiHBcActot (-) and HBsAg (-) at baseline were included, none of them had received prior HBV vaccination. HBV adjuvanted vaccine was used in a 4-dose regimen (0-1-2-6 months). When antiHBs was <10 IU/mL after primovaccination, two additional doses of the same vaccine were applied with an interval of 30 days. Results. A total of 39 patients were included. Of them, 74.4% were men. The mean age was 47.26 years. The response rate after primary vaccination was higher than 92% and up to 100% with the two subsequent doses. No adverse reactions were reported. Conclusion. The administration of AS04C-adjuvanted hepatitis B vaccine in HIV patients showed a 100% response rate, showing an excellent safety profile

Asunto(s)